Received Dec 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 4 | P2443 | — |
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | — | — |
patient got 4 doses of Twinrix; Wrong interval administration/ 2nd dose received on 18-MAY-2023 and 3rd dose received on 25-MAR-2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 65-year-old patient who received HAB (Twinrix) for prophylaxis. Co-suspect products included HAB (Twinrix) (batch number P2443, expiry date 18-SEP-2027) for prophylaxis. Previously administered products included Twinrix (first dose received on 14-APR-2023) and Twinrix (second dose received on 18-MAY-2023). On 25-MAR-2025, the patient received the 3rd dose of Twinrix. On 03-JUL-2025, the patient received the 4th dose of Twinrix. On 25-MAR-2025, an unknown time after receiving Twinrix and not applicable after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Wrong interval administration/ 2nd dose received on 18-MAY-2023 and 3rd dose received on 25-MAR-2025). On 03-JUL-2025, the patient experienced extra dose administered (Verbatim: patient got 4 doses of Twinrix). The outcome of the drug dose administration interval too long and extra dose administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 20-NOV-2025 The pharmacist called seeking guidance regarding the Twinrix vaccine series. The pharmacist wanted to know whether a booster dose was required or if the complete vaccine series needed to be restarted. The vaccine administration facility was the same as the primary reporter. The batch number was not provided upon follow- up with the reporter. This was 1 of 3 linked cases, reported by the same reporter.; Sender's Comments: US-GSK-US2025150964:Same Reporter US-GSK-US2025151087:Same Reporter